Antimony oxidation states in antileishmanial drugs

Am J Trop Med Hyg. 1995 May;52(5):435-7. doi: 10.4269/ajtmh.1995.52.435.

Abstract

Chemical methods specific for the determination of the levels of trivalent antimony (Sb+3) and pentavalent antimony (Sb+5) were used to investigate proprietary formulas used to treat leishmaniasis. Trivalent antimony was determined by differential pulse polarography, whereas Sb+5 was determined by iodine titration. Proprietary formulas based on N-meglumine antimoniate (Glucantime) were analyzed in detail. The results showed Sb+3 in all ampules of Glucantime. In formulations said to contain either 85 or 100 mg of Sb+5/ml, we found both forms of antimony. The amount of Sb+3 ranged from 10.5 to 15.8% (10.06-18.96 mg of Sb/ml). These findings raise issues on product stability and standardization and may help to clarify resistance to antimonial drugs and the reducing effect of tissue on Sb+5.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimony / analysis
  • Antimony / metabolism*
  • Antimony Sodium Gluconate / chemistry*
  • Antimony Sodium Gluconate / standards
  • Antiprotozoal Agents / chemistry*
  • Antiprotozoal Agents / standards
  • Drug Stability
  • Meglumine / chemistry*
  • Meglumine / standards
  • Meglumine Antimoniate
  • Organometallic Compounds / chemistry*
  • Organometallic Compounds / standards
  • Oxidation-Reduction

Substances

  • Antiprotozoal Agents
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate
  • Antimony
  • Antimony Sodium Gluconate